S
Salomon M. Stemmer
Researcher at Rabin Medical Center
Publications - 215
Citations - 12740
Salomon M. Stemmer is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 43, co-authored 189 publications receiving 9651 citations. Previous affiliations of Salomon M. Stemmer include University of New South Wales & Tel Aviv University.
Papers
More filters
Proceedings ArticleDOI
Abstract P5-20-01: A randomized double-blind phase II study of the combination of oral WX-671 plus capecitabine vs. capecitabine monotherapy in first-line HER2− negative metastatic breast cancer (MBC).
Lori J. Goldstein,CT Oliveria,Bernhard Heinrich,Salomon M. Stemmer,C. Mala,S Selder,Paul Bevan,Nadia Harbeck +7 more
TL;DR: This proof of concept study is designed to substantiate the anti-metastatic properties of upamostat for patients appropriate for first line therapy for MBC and to assess the pharmacokinetics (PK) of up amostat and capecitabine when combined.
Journal Article
Weekly infusional high-dose 5-fluorouracil and leucovorin and biweekly cisplatin: a convenient treatment option in advanced gastric cancer.
Yulia Kundel,Ofer Purim,Arie Figer,Salomon M. Stemmer,Thomas Tichler,Jaqueline Sulkes,Aaron Sulkes,Baruch Brenner +7 more
TL;DR: This regimen appears safe, with a manageable toxicity profile, and Efficacy data resemble those reported for more complex and toxic regimens.
Journal ArticleDOI
First Efficacy Results From the Turandot Phase III Trial Comparing Two Bevacizumab (BEV)-Containing Regimens as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MBC)
Christoph C. Zielinski,István Láng,Moshe Inbar,Zsuzsanna Kahán,Richard Greil,Semir Beslija,Salomon M. Stemmer,Bella Kaufman,Zanete Zvirbule,Günther G. Steger,Bohuslav Melichar,Tadeusz Pienkowski,D. Sirbu,Lubos Petruzelka,Alexandru Eniu,Bella Nisenbaum,Magdolna Dank,Rodica Anghel,D. Messinger,Thomas Brodowicz +19 more
TL;DR: The TURANDOT trial as discussed by the authors compared paclitaxel (PAC) and capecitabine (CAP) with BEV until disease progression or unacceptable toxicity and showed non-inferior overall survival (OS) with PAC vs BEV-CAP.
Journal ArticleDOI
Doxorubicin-Induced Apoptosis in Germinal Vesicle Oocytes.
Journal ArticleDOI
A phase II, multi-center study of a new non-cytotoxic A3 adenosine receptor agonist CF101, dose-finding (randomized blinded) in patients (pts) with refractory metastatic colorectal cancer
Salomon M. Stemmer,Adi Shani,B. Klein,Michael H Silverman,I. Lorber,Motti Farbstein,E. Shmueli,Arie Figer +7 more
TL;DR: Oral CF101 has been shown to inhibit colon, prostate, melanoma, pancreatic and hepatocellular cancer growth in experimental animal models, via down-regulation of the Wnt and NF-κB signal transduction pathways.